Charity coverage and decreased COVID-19 mortality among uninsured patients in Texas: A retrospective cohort study
PLOS One · 2025
DOI: 10.1371/journal.pone.0330533 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS One, 2025. Verfasst von Anisha P Ganguly und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. Hauptthemen laut MEDLINE: COVID-19, Medically Uninsured, Charities. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Purpose
Decreased access to care and social drivers of health have been implicated in COVID-19 disparities. The objective of this study was to test the association between county-funded charity coverage (CFCC) and mortality among uninsured patients hospitalized with COVID-19 in a highly uninsured county.
Methods
This retrospective cohort study compared electronic health record (EHR) data among uninsured patients hospitalized with COVID-19 in a high-volume safety-net health system in Dallas County, Texas between June 2020 and December 2021. Uninsured patients included CFCC recipients and self-pay patients. We compared mortality over 180 days of follow-up using Cox proportional hazards models, adjusting for gender, age, race/ethnicity, and co-morbidities. Additional outcomes included 90-day mortality, need for mechanical ventilation, and intubation within 24 hours of presentation.
Results
Among 2,047 patients, 47.0% received CFCC and 53.0% were self-pay. Overall, CFCC patients were older, more likely Hispanic, and had more diagnosed co-morbidities. CFCC patients had decreased adjusted mortality compared to self-pay (aHR 0.61, 95% CI [0.45 to 0.82], p < 0.01), with an absolute risk reduction of 3.3% and a number needed to treat (NNT) with CFCC of 30.4 (95% CI 21.4–66.6). CFCC was associated with lower 90-day mortality compared to self-pay (OR = 0.64, 95% CI [0.45–0.92], p = 0.01), despite similar need for ventilation. Intubation within 24 hours of presentation was lower for CFCC compared to self-pay (OR = 0.46, 95% CI [0.22–0.93], p = 0.03).
Conclusions
CFCC was associated with decreased mortality among the uninsured hospitalized with COVID-19. The NNT for CFCC to prevent 1 death among uninsured patients was similar to that for standard medications to treat COVID-19. These findings support expanding coverage to improve COVID-19 outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
- Center of Innovation and Value, Parkland Health, Dallas, Texas, United States of America.
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
- O'Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
ORCID-Profile: Anisha P Ganguly, Robert W Haley, Kavita P Bhavan
Förderung
- Gilead Sciences
Zitieren
APA
Ganguly, A. P., Battaile, J. T., Harms, M., Murray, S., Gurley, T., Haley, R. W., Jain, M. K., & Bhavan, K. P. (2025). Charity coverage and decreased COVID-19 mortality among uninsured patients in Texas: A retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0330533
Vancouver
Ganguly AP, Battaile JT, Harms M, Murray S, Gurley T, Haley RW, et al. Charity coverage and decreased COVID-19 mortality among uninsured patients in Texas: A retrospective cohort study. PLOS One. 2025. doi:10.1371/journal.pone.0330533
BibTeX
@article{Ganguly2025,
author = {Ganguly, Anisha P and Battaile, John T and Harms, Michael and Murray, Shannon and Gurley, Tami and Haley, Robert W and Jain, Mamta K and Bhavan, Kavita P},
title = {Charity coverage and decreased COVID-19 mortality among uninsured patients in Texas: A retrospective cohort study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0330533}
}
EUVIMED